Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66594 | 0.69 | TSHR (0.35) | — | |
| SCHEMBL7817367 | 0.64 | MAPK1 (0.39) | CYP3A4MAPK1ALDH1A1POLBHSD11B1 | |
| SCHEMBL7868500 | 0.62 | HPGD (0.33) | CYP3A4TP53RAPGEF4KDM4EMEN1 | |
| SCHEMBL209538 | 0.61 | TP53 (0.33) | CYP3A4MAPK1ALDH1A1TP53NR4A2 | |
| SCHEMBL322631 | 0.61 | TP53 (0.33) | CYP3A4ALDH1A1TP53KDM4EMEN1 | |
| SCHEMBL323047 | 0.58 | MAPK1 (0.41) | CYP3A4MAPK1ALDH1A1POLBHSD11B1 | |
| SCHEMBL5953558 | 0.58 | DRD2 (0.38) | CYP3A4 | |
| SCHEMBL2327323 | 0.58 | TP53 (0.35) | CYP3A4MAPK1ALDH1A1POLBTP53 | |
| SCHEMBL9092157 | 0.58 | HSD11B1 (0.39) | CYP3A4POLBHSD11B1TP53RAPGEF4 | |
| SCHEMBL14743082 | 0.58 | S100A4 (0.44) | CYP3A4ALDH1A1TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629138-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3692029-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3692029-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2020-08-12 | — | — | EP | disclosed |
| CN-111194314-A | Microbicidal picolinamide derivatives | 先正达参股股份有限公司 | 2020-05-22 | — | — | CN | disclosed |
| WO-2019068809-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | PRF1, CASP1, FPR1 | CYP3A4 587/4885MAPK1 3249/4885ALDH1A1 1067/4885 |
| US-11629138-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | CYP3A4 587/4885MAPK1 3249/4885ALDH1A1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.